You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

High Risk of Recurrence Melanoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Improve Early Detection of Cancer Recurrence in High-Risk

Recruiting
  • Stage III Melanoma
  • Stage IV Cutaneous Melanoma
    • Cleveland, Ohio
      Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
    Oct 6, 2022

    Melanoma Trial (Blood samples, Skin biopsy)

    Not yet recruiting
    • Melanoma
    • Blood samples
    • Skin biopsy
    • (no location specified)
    Oct 3, 2022

    Melanoma Trial in New York (DC Vaccine, Montanide Vaccine, Poly-ICLC)

    Completed
    • Melanoma
    • DC Vaccine
    • +2 more
    • New York, New York
    • +1 more
    Sep 13, 2022

    Melanoma Trial in Jette, Brussels (follow up DW MRI)

    Recruiting
    • Melanoma
    • follow up DW MRI
    • Jette, Brabant, Belgium
    • +1 more
    Dec 16, 2020

    Melanoma Trial in Nedlands, Haifa, Jerusalem (Pembrolizumab/Vibostolimab, Pembrolizumab)

    Recruiting
    • Melanoma
    • Pembrolizumab/Vibostolimab
    • Pembrolizumab
    • Nedlands, Western Australia, Australia
    • +2 more
    Jan 31, 2023

    Clinical Stage IIA Cutaneous Melanoma AJCC v8 Trial in Portland (drug, procedure, other)

    Not yet recruiting
    • Clinical Stage IIA Cutaneous Melanoma AJCC v8
    • Portland, Oregon
      OHSU Knight Cancer Institute
    Nov 27, 2023

    Melanoma Trial (V940, Pembrolizumab, Placebo)

    Not yet recruiting
    • Melanoma
    • V940
    • +2 more
    • (no location specified)
    Jul 12, 2023

    Stage II Melanoma Trial in Wollstonecraft (Relatlimab and nivolumab fixed dose combination (FDC))

    Not yet recruiting
    • Stage II Melanoma
    • Relatlimab and nivolumab fixed dose combination (FDC)
    • Wollstonecraft, New South Wales, Australia
      Melanoma Institute Australia
    Oct 26, 2022

    Melanoma, Acral Melanoma, Temozolomide Trial (Camrelizumab)

    Not yet recruiting
    • Melanoma
    • +6 more
    • (no location specified)
    Aug 21, 2022

    Melanoma Trial (pembrolizumab, )

    Active, not recruiting
    Has Results
    • Melanoma
    • pembrolizumab
    • placebo
    • (no location specified)
    Aug 18, 2022

    Radiotherapy, Immunotherapy, Liver Metastases Trial in Shanghai (SBRT, Chemotherapy, PD-1 antibody)

    Recruiting
    • Radiotherapy
    • +3 more
    • SBRT
    • +2 more
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Nov 2, 2023

    Melanoma, Skin Cancer, Anxiety and Fear Trial in Australia (2D or 3D Melanoma Surveillance Photography)

    Recruiting
    • Melanoma
    • +2 more
    • 2D or 3D Melanoma Surveillance Photography
    • Camperdown, New South Wales, Australia
    • +11 more
    Aug 22, 2022

    Malignant Melanoma Trial (Fluvastatin, RNA-sequencing, Gene expression profiling)

    Withdrawn
    • Malignant Melanoma
    • (no location specified)
    Jul 23, 2020

    Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous

    Recruiting
    • Clinical Stage III Cutaneous Melanoma AJCC v8
    • +5 more
    • Jacksonville, Florida
    • +2 more
    Oct 21, 2022

    Clinical Research of Drug Holiday Based on MRD Detection in GIST

    Recruiting
    • Gastrointestinal Stromal Tumors
      • Beijing, Beijing, China
        Peking University People's Hospital
      May 11, 2023

      Durvalumab, Intrahepatic Cholangiocarcinoma, Gemcis Trial in Tianjin (Durvalumab, Surgery, Gemcitabine)

      Recruiting
      • Durvalumab
      • +2 more
      • Tianjin, Tianjin, China
        Tianjin Medical University Cancer Institute and Hospital
      Jan 3, 2023

      Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma Trial in Beijing (multi-kinase inhibitors in

      Not yet recruiting
      • Liver Transplant; Complications
      • +3 more
      • multi-kinase inhibitors in combination with bevacizumab
      • Beijing, Beijing, China
        Chinese Academy of Medical Sciences & Peking Union Medical Colle
      Sep 11, 2023

      Melanoma Trial in Knoxville (Fianlimab, Cemiplimab, Pembrolizumab)

      Recruiting
      • Melanoma
      • Knoxville, Tennessee
        University of Tennessee Medical Center
      Dec 20, 2022

      Hepatocellular Carcinoma, Recurrence, Immune Checkpoint Inhibitor Trial in Nanning (Adjuvant tislelizumab plus lenvatinib,

      Not yet recruiting
      • Hepatocellular Carcinoma
      • +2 more
      • Adjuvant tislelizumab plus lenvatinib
      • Adjuvant tislelizumab
      • Nanning, China
        Jian-Hong Zhong
      Jun 11, 2023

      Prostate Cancer, Biochemical Recurrence, High Risk Trial in Nanjing, Nantong (Apalutamide 60mg Tab, Androgen deprivation

      Not yet recruiting
      • Prostate Cancer
      • +2 more
      • Apalutamide 60mg Tab
      • Androgen deprivation therapy(ADT)
      • Nanjing, Jiangsu, China
      • +2 more
      Mar 17, 2023

      Melanoma, Ocular Melanoma Trial in United States (Nivolumab, Ipilimumab)

      Active, not recruiting
      • Melanoma
      • Ocular Melanoma
      • San Francisco, California
      • +5 more
      Aug 31, 2022

      Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

      Recruiting
      • Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
      • Shanghai, Shanghai, China
        Zhongshan Hospital, Fudan University
      Jan 4, 2023

      Leukemia, Myeloid, Acute Trial in Chengdu (Chidamide)

      Recruiting
      • Leukemia, Myeloid, Acute
      • Chengdu, Sichuan, China
        West China Hospital of Sichuan University
      Dec 27, 2022

      Melanoma Trial in Australia, United States (mRNA-4157, Pembrolizumab)

      Active, not recruiting
      • Melanoma
      • mRNA-4157
      • Pembrolizumab
      • Tucson, Arizona
      • +21 more
      Aug 23, 2022

      Hepatocellular Carcinoma Trial (Donafenib + Tislelizumab)

      Not yet recruiting
      • Hepatocellular Carcinoma
      • Donafenib + Tislelizumab
      • (no location specified)
      Sep 15, 2022